Pantoprazole is a proton pump inhibitor that inhibits H+/K+-ATPase activity in porcine gastric membrane vesicles with an IC50 value of 6.8 ?M.1 It reduces basal gastric acid secretion in pylorus-ligated rats (ED50 = 1.3 mg/kg) and inhibits mepirizole-induced increases in gastric acid secretion in an anesthetized rat model of gastric fistula (ED50 = 0.8 mg/kg).2 Pantoprazole inhibits formation of mepirizole-induced duodenal lesions in rats (ED50 = 0.5 mg/kg). Formulations containing pantoprazole have been used in the treatment of gastroesophageal reflux disease (GERD) and hypersecretory conditions, including Zollinger-Ellison Syndrome.
1.Beil, W., Staar, U., and Sewing, K.F.Pantoprazole: A novel H+/K+-ATPase inhibitor with an improved pH stabilityEur. J. Pharmacol.218(2-3)265-271(1992) 2.Takeuchi, K., Konaka, A., Nishijima, M., et al.Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: A comparative study with omeprazole and lansoprazoleJ. Gastroenterol. Hepatol.14(3)251-257(1999)